Insider buying last 90 days
No open-market insider purchases were filed for KRYS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Krystal Biotech's week centers on third-quarter results and the market reaction to them. The company reported VYJUVEK revenue of $127.3 million, up 30% year-over-year, diluted EPS of $2.05 against a consensus estimate of $1.79, and $1.2 billion in cash, while the board authorized a $400 million share repurchase program over two years. Despite the beat and buyback news, the stock fell 8.2% on the reaction, which one analyst characterized as "overblown." Separately, Citigroup and TD Cowen each maintained Buy ratings while trimming price targets to $412 and $380 respectively, and the stock carries a broader "Moderate Buy" consensus from covering analysts.
The stock closed at $303.06, up 0.7%, sitting between its 50-day average of $331.52 and 200-day average of $309.12, with one-month and three-month returns of -8.6% and -7.3% respectively against a one-year return of 51.6%. The GekkoIndex reads 66.1, placing it in the Accumulation zone. Price sits 28.9% below Gekko Fair Value of $426.17.
The next earnings date falls on 16 February 2027, outside a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in the current windows. Seasonally, the next 20 trading days have averaged a 10.6% return over five years, though gains occurred in only 2 of those years. The consensus price target stands at $388.22, implying 28.1% upside from current levels.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Krystal Biotech scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
Averages disagree
Close $305.23 sits between the 50-day ($326.77) and 200-day ($309.71) averages, or the averages disagree.
See the chart62.5, Accumulation
Reading 62.5 is in the Accumulation zone.
See the GekkoIndex25.9% below
Price is 25.9% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 93 days
Next report Feb 16, 2027, 93 days away — outside a typical 20-trading-day hold.
See earnings+13.5% on average
From this point in the calendar, the next 20 trading days averaged +13.5% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Krystal Biotech closed at $305.23 on Nov 13, 2026, +50.3% over the past year, inside a 52-week range of $198.02 to $382.54.
Use the left and right arrow keys to read daily values.
Put KRYS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Krystal Biotech works on gene therapies designed to be given more than once, aimed at rare and severe diseases that currently have few treatment options. Its furthest-along candidate, beremagene geperpavec, is in Phase III testing for dystrophic epidermolysis bullosa, a skin condition, and this program is the one most associated with the company.
Beyond that lead candidate, Krystal Biotech runs a broader pipeline at different stages. KB105 and KB301 are in Phase I/II trials, treating autosomal recessive congenital ichthyosis and aiming to address skin wrinkling and damage respectively. KB407 for cystic fibrosis and KB104 for Netherton syndrome remain in preclinical testing, while earlier-stage work includes KB5xx candidates for chronic skin conditions and several KB3xx programs focused on dermatological aesthetic issues.
Krystal Biotech was founded in 2015 and operates out of Pittsburgh, Pennsylvania. Its shares are listed on the NASDAQ under the ticker KRYS.
Krystal Biotech’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 62.5, in the Accumulation zone, down 4.9 points over five sessions.
Down 4.9 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 20 | −1.7% | +25.2% | ||
| Accumulation (current zone) | 221 | +2.9% | +4.8% | ||
| Neutral | 409 | 0.0% | +2.3% | ||
| Distribution | 51 | −0.3% | +2.6% | ||
| Selling | 1 | Too few readings yet | |||
Average KRYS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Krystal Biotech trades 25.9% below Gekko Fair Value of $412.15, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Krystal Biotech shares are worth, recalculated every trading day.
$412.15
Gekko Fair Value, Nov 14, 2026
25.9% Undervalued
At the end of Aug 2026 the price was 16.2% below the estimate.
No open-market insider purchases were filed for Krystal Biotech, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for KRYS in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in KRYS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Krystal Biotech has been buying back its own shares.
From company filings.
Krystal Biotech reports on Feb 16, 2027, before the open (93 days away), and beat the EPS estimate in 7 of its last 8 reports.
Feb 16, 2027
Expected before the open, 93 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 2, 2026 | $2.05 est $1.79 | $127.3M est $125.8M | −8.2% |
| Aug 3, 2026 | $1.79 est $1.70 | $119.2M est $120.9M | −4.8% |
| May 4, 2026 | $1.83 est $1.46 | $116.4M est $112.1M | +7.0% |
| Feb 17, 2026 | $1.70 est $1.62 | $107.1M est $105.3M | +2.5% |
| Nov 3, 2025 | $2.66 est $1.12 | $97.80M est $105.3M | +2.9% |
| Aug 4, 2025 | $1.29 est $1.08 | $96.04M est $95.41M | −12.5% |
| May 6, 2025 | $1.20 est $1.03 | $88.18M est $106.0M | −15.7% |
| Feb 19, 2025 | $1.53 est $1.85 | $91.14M est $91.35M | +16.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Krystal Biotech is $388.22, +27.2% from the last close, from 6 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 6 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 6 | RBC Capital | $375 | +22.9% |
| Nov 3 | Citi | $412 | +35.0% |
| Nov 3 | TD Cowen | $380 | +24.5% |
| Nov 2 | RBC Capital | $375 | +22.9% |
| Nov 2 | H.C. Wainwright | $361 | +18.3% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Krystal Biotech averaged +13.5% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.7% | 1 of 5 |
| Next 10 trading days | +15.6% | 3 of 5 |
| Next 15 trading days | +11.9% | 2 of 5 |
| Next 20 trading days | +13.5% | 3 of 5 |
| Next 30 trading days | +15.7% | 3 of 5 |
For scale, KRYS’s typical 20-trading-day move in either direction is about 7.8%.
Krystal Biotech’s market cap is $9.05B, with a P/E ratio of 41.5 and revenue of $470.0M over the last twelve months.
Coverage of Krystal Biotech this week reads neutral: 0 positive, 3 neutral and 0 negative headlines.
Krystal Biotech’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 19.9% below |
| GILDGilead Sciences | Neutral | 11.7% above |
| MRNAModerna | Neutral | 21.1% above |
| NTRANatera | Accumulation | 18.6% below |
| IQVIQVIA | Accumulation | 5.0% above |
| UTHRUnited Therapeutics | Neutral | 11.2% below |
A peer links to its own page where one exists.
Krystal Biotech’s market cap is $9.05B at the Nov 13, 2026 close of $305.23, with 29.63M shares outstanding. The shares trade on a P/E ratio of 41.5.
The consensus analyst 12-month price target for Krystal Biotech is $388.22, +27.2% from the last close. Of the 6 firms that rated the stock in the last 90 days, 6 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Krystal Biotech is undervalued: the Nov 13, 2026 close of $305.23 is 25.9% below Gekko Fair Value of $412.15. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Krystal Biotech is expected to report on Feb 16, 2027, before the market opens (93 days away). Analysts expect earnings of $2.04 per share on revenue of $134.0M. Krystal Biotech beat the earnings estimate in 7 of its last 8 reports, moving 8.8% on average across the report.
Krystal Biotech’s 52-week high is $382.54 and its 52-week low is $198.02; it closed at $305.23 on Nov 13, 2026, +50.3% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.